Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform - Johnson & Johnson
Source:Jnj.com
• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens lead…
Related Articles
OpenAI hit with lawsuit by Florida AG over AI risks - Politico
It is the first such lawsuit to be filed by a state against OpenAI and Sam Altman.
It's called 'private credit' — and it could lead to big trouble on Wall Street - NPR
The risky lending business has been booming — but now its problems are becoming increasingly visible …
The hot new commute for Miami billionaires costs $1,000 a minute - Business Insider
Miami’s ultrarich residents are spending thousands on ILandMiami’s mobile, floating …
Stephen Miran resigns from the White House, keeping his seat at the Fed - CNN
Stephen Miran, one of President Donald Trump’s top economists, on Tuesday resigned from his …